[DCTH] Delcath Systems, Inc.


Type of security: Stock

Sector: Health Care

Industry: Medical/Dental Instruments

Market Capitalization: 6.51 M

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 1.09 Change: 0.04 (3.81%)
Ext. hours: Change: 0 (0%)

chart DCTH

Refresh chart

Description: Delcath Systems, Inc. operates as a specialty pharmaceutical and medical device company focusing on the field of oncology in the United States and internationally. The company?s proprietary technology enables the administration of high-dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic exposure of those agents. It is primarily involved in the development of CHEMOSAT/Melphalan hepatic delivery system that administers concentrated regional chemotherapy to the liver. Delcath Systems, Inc. was founded in 1988 and is headquartered in New York, New York.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding24.12 M EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 76.89% Sales Growth - Q/Q52.58% P/E
P/E To EPS Growth P/S5.41 P/BV0.4 Price/Cash Per Share
Price/Free Cash Flow-0.42 ROA-72.01% ROE-94.93% ROI
Current Ratio4.73 Quick Ratio4.66 Long Term Debt/Equity Debt Ratio0.26
Gross Margin72.49% Operating Margin-1492.35% Net Profit Margin-1296.01% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities2.48 M Cash From Investing Activities-40 K Cash From Operating Activities-4.41 M Gross Profit310 K
Net Profit-3.49 M Operating Profit-3.71 M Total Assets21.65 M Total Current Assets20.03 M
Total Current Liabilities4.24 M Total Debt Total Liabilities5.23 M Total Revenue440 K
Technical Data
High 52 week2.27 Low 52 week0.02 Last close0.05 Last change2.22%
RSI54.44 Average true range0.02 Beta0.68 Volume473.5 K
Simple moving average 20 days-16.13% Simple moving average 50 days-9.06% Simple moving average 200 days-48.3%
Performance Data
Performance Week-17.12% Performance Month29.58% Performance Quart-58.18% Performance Half130%
Performance Year-97.7% Performance Year-to-date-95% Volatility daily30.58% Volatility weekly68.38%
Volatility monthly140.13% Volatility yearly485.43% Relative Volume837.53% Average Volume22.46 M
New High New Low


2019-09-19 10:15:00 | MicroCap Rodeo Investor Conference - October 15 and 16, 2019, Austin Texas

2019-08-28 08:00:00 | Delcath Systems Announces Presentation at the Rodman & Renshaw 21st Annual Global Investment Conference sponsored by H.C. Wainwright

2019-08-20 08:00:00 | Delcath Systems Closes $9.5 Million Private Placement

2019-08-15 18:02:02 | Delcath Systems Announces $9.5 Million Private Placement

2019-07-29 08:00:00 | Delcath Enhances Board of Directors With Appointment of Commercial Leader, John R. Sylvester

2019-07-22 08:00:00 | Results of Single Center Study on Delcath’s PHP Therapy Published in Cancer Imaging

2019-07-17 16:05:00 | Delcath Systems Closes $20 Million Private Placement

2019-07-11 13:40:28 | Delcath Systems Announces $20 Million Private Placement

2019-04-16 08:15:00 | Results of Single Center Prospective Study on Delcath’s PHP Therapy Presented at ECIO 2019

2019-02-28 10:38:14 | Delcath Joins the Ocular Melanoma Community in Recognizing Rare Disease Day

2019-02-11 08:00:00 | Delcath Announces Health Authority Approval for CHEMOSAT in Brazil

2019-02-08 08:00:00 | Delcath Announces Acceptance of Abstract for Oral Presentation at ECIO 2019

2018-12-26 08:00:00 | Delcath Announces Commercial Licensing Agreement for CHEMOSAT®

2018-12-18 08:00:00 | Delcath Announces 4th Independent Safety Review of Registration Trial Data for Metastatic Ocular Melanoma: Recommended Continuation with no Trial Modification

2018-11-13 16:52:27 | Delcath Announces Third Quarter Fiscal 2018 Financial Results

2018-10-18 08:00:00 | Delcath Announces Enrollment of First Patient in ALIGN Trial

2018-10-15 08:00:00 | Delcath Expands Rollout of Registration Trial in Metastatic Ocular Melanoma

2018-10-04 08:00:00 | Multi-center Analysis of Outcomes Data on Use of Delcath CHEMOSAT in the Treatment of ICC Published in European Radiology

2018-09-27 16:05:00 | Delcath Raises $8.1 Million from Shareholders in Rights Offering

2018-09-26 08:00:00 | Data from Prospective Phase 2 Study Investigating Delcath’s PHP Therapy presented at CIRSE 2018

2018-09-24 08:00:00 | Data on Delcath’s PHP Therapy presented at CIRSE 2018

2018-09-13 08:00:00 | Delcath Reminds Shareholders that the Rights Offering Subscription Period Expires Wednesday, September 26, 2018

2018-09-04 08:00:00 | Multi-center Analysis of Outcomes Data on Use of Delcath CHEMOSAT in the Treatment of ICC to be Published in European Radiology

2018-08-28 08:33:16 | Delcath Announces Extension of Rights Offering Period to September 26, 2018

2018-08-27 09:00:00 | Delcath Announces Acceptance of Abstract for Poster Presentation at CIRSE 2018

2018-08-23 11:14:15 | Delcath Announces 3rd Independent Safety Review of Randomized Trial Data for Metastatic Ocular Melanoma; Recommended Continuation with no Trial Modification

2018-08-22 09:41:33 | Delcath Announces Pending Expiration to Rights Offering Subscription Period

2018-08-21 08:52:31 | First Patient Enrolled in Delcath Amended Registration Trial in Metastatic Ocular Melanoma

2018-08-20 08:00:00 | Delcath Announces Beginning of Enrollment of Amended Metastatic Ocular Melanoma Registration Trial

2018-08-17 08:00:00 | Delcath Issues Letter to Stockholders

2018-08-15 08:00:00 | Delcath Announces Second Quarter Fiscal 2018 Financial Results

2018-08-06 08:00:00 | Delcath Announces Commencement of Rights Offering Subscription Period

2018-07-31 08:00:00 | Summary of Calendar for Upcoming Proposed Delcath Rights Offering

2018-07-27 08:00:00 | Delcath Amends Phase 3 Ocular Melanoma Trial Protocol

2018-07-16 08:00:00 | Delcath Systems Announces Rights Offering and Backstop Commitment Ownership Date of August 1, 2018

2018-07-09 08:00:00 | Delcath Announces 100th Commercial CHEMOSAT Treatment Completed at Leiden University Medical Center, The Netherlands

2018-05-29 08:30:00 | Delcath Systems to Present at the 8th Annual LD Micro Invitational

2018-05-22 08:15:00 | Delcath Sponsors Looking For A Cure Ocular Melanoma Charity Event

2018-05-16 08:00:00 | Delcath’s CHEMOSAT Included in German Treatment Guidelines for Melanoma Liver Metastases

2018-05-14 08:00:00 | Delcath’s PHP Therapy Featured in Video Learning Session at the European Conference of Interventional Oncology 

2018-05-10 08:00:00 | Delcath Announces First Quarter 2018 Financial Results

2018-05-07 08:00:00 | Delcath Announces Initiation of Registrational Trial of Melphalan/HDS in Intrahepatic Cholangiocarcinoma

2018-05-04 09:29:31 | Delcath to Present at the RHK Capital 2018 Disruptive Growth and Healthcare Conference

2018-05-03 08:30:00 | Delcath Announces Another DSMB Recommendation for Phase 3 Focus Trial

2018-05-01 08:00:00 | Delcath Announces Ratio for Reverse Split Authorization

2018-04-09 08:00:00 | Delcath Announces Shareholder Approval of Consent Solicitation

2018-04-03 08:00:00 | Delcath’s PHP Therapy to be Featured in Video Training Session at European Conference of Interventional Oncology  

2018-03-29 08:00:00 | Summary of Recent Published Research on Delcath’s PHP Therapy Presented at Society of Surgical Oncology Annual Symposia

2018-03-19 16:05:00 | Delcath to Present at Oppenheimer 28th Annual Healthcare Conference

2018-03-16 09:00:00 | Delcath Announces 2017 Financial Results